A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.
“First, Congress could explicitly allow the participation of
…
Small rural hospitals have lost on average 39% of their 340B contract pharmacy savings due to drug manufacturers’ conditions on 340B pricing while larger, mostly urban hospitals have lost on average 23%, a hospital group’s member survey shows.
The finding
…
Prescription drug sales at 340B-discounted prices grew 15.9% year-on-year from 2020 to 2021, drug industry consulting and contract research firm IQVIA reports, an annual growth rate below that for the two preceding years.
Last year, IQVIA reported that 340B sales
…
The exclusion of 340B pricing for some hospitals on drugs to treat orphan conditions and diseases could be partially eliminated to slow “the rapid growth in approved rare disease treatments” and “their cumulative affordability to the health system,” an influential
…
Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.
The Centers for Medicare & Medicaid Services (CMS) Office of the Actuary
…
Charity care has been declining significantly in some Massachusetts hospital systems, raising “a significant policy issue for the 340B program,” a free-market-oriented Massachusetts think tank whose donors include pharmaceutical manufacturers says in a new report.
The state hospital association said
…
Contract pharmacy growth patterns differ between 340B hospital and non-hospital entities, suggesting they may use 340B differently and should be subject to different 340B rules, new research in the American Journal of Managed Care concludes.
The authors, who previously have
…
New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s
…
Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.
Lujan’s chief of staff
The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost effectiveness
…*Sign up for news summaries and alerts from 340B Report